Nature Reviews Cancer最新文献_第2页

A fatty competitor in tumour immunity 肿瘤免疫中的脂肪竞争者。

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2026-03-31 DOI: 10.1038/s41568-026-00927-x

Gabrielle Brewer

引用次数: 0

Targeting shared neoantigens in solid tumours. 实体肿瘤中共同的新抗原靶向。

IF 78.5 1区医学

Nature Reviews Cancer Pub Date : 2026-03-30 DOI: 10.1038/s41568-026-00925-z

Luis I Terrazas,Alberto N Peón

引用次数: 0

AI-driven smart patient retrieval for precision oncology 人工智能驱动的精准肿瘤学智能患者检索。

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2026-03-26 DOI: 10.1038/s41568-026-00923-1

Yan-Ran Joyce Wang, Akshay S. Chaudhari

引用次数: 0

Functional m6A site detection by FOCAS FOCAS检测功能性m6A位点

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2026-03-25 DOI: 10.1038/s41568-026-00926-y

Yifan Zhang

引用次数: 0

Striking the right balance with type I interferon signalling in cancer. 与I型干扰素信号在癌症中的正确平衡。

IF 78.5 1区医学

Nature Reviews Cancer Pub Date : 2026-03-23 DOI: 10.1038/s41568-026-00915-1

Thomas B Chadwick,Joan So,Paul J Hertzog,Nicole M Haynes,Belinda S Parker

{"title":"Striking the right balance with type I interferon signalling in cancer.","authors":"Thomas B Chadwick,Joan So,Paul J Hertzog,Nicole M Haynes,Belinda S Parker","doi":"10.1038/s41568-026-00915-1","DOIUrl":"https://doi.org/10.1038/s41568-026-00915-1","url":null,"abstract":"Type I interferons (IFNs), particularly IFNα and IFNβ, have an important role in cancer therapy, enhancing antitumour immunity and improving the efficacy of both conventional treatments and immunotherapies. However, despite considerable investment and research in IFN-based treatments, clinical success in solid malignancies has been hampered by toxicity and limited therapeutic efficacy. Recent studies show that type I IFNs can exert both immune-stimulatory and immune-suppressive effects within tumours, with their activity shaped by oncogenic signalling, chromatin state, the tumour microenvironment and therapeutic interventions. In this Review, we explore current insights into the regulation and function of type I IFNs in cancer, with a particular focus on tumour-intrinsic mechanisms controlling canonical and chronic signalling. We examine how these pathways influence immune surveillance, metastatic progression, therapeutic response and resistance. We also discuss how age-related changes, including immunosenescence and alterations in stromal composition and function, modulate type I IFN signalling and affect therapeutic outcomes. By dissecting the transcriptional, epigenetic and signalling mechanisms that control type I IFN responses, we outline actionable strategies to reprogramme IFN activity in tumours and ultimately improve response to therapies.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"20 1","pages":""},"PeriodicalIF":78.5,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Avoiding cancer through collective behaviour 通过集体行为避免癌症。

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2026-03-20 DOI: 10.1038/s41568-026-00924-0

Victoria Rodríguez-Lelis, Mariana Gómez-Schiavon

引用次数: 0

Metabolic vulnerability in fusion-driven ependymoma 融合驱动型室管膜瘤的代谢易感性。

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2026-03-12 DOI: 10.1038/s41568-026-00920-4

Daniela Senft

引用次数: 0

Re-routing IgE for cancer therapy 将IgE重新用于癌症治疗。

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2026-03-06 DOI: 10.1038/s41568-026-00917-z

Gabrielle Brewer

引用次数: 0

Claudin proteins as emerging therapeutic targets for solid tumours Claudin蛋白作为实体肿瘤的新治疗靶点。

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2026-03-02 DOI: 10.1038/s41568-026-00913-3

Antonio Saviano, Alberto Toso, Samuel J. Klempner, Thomas F. Baumert

{"title":"Claudin proteins as emerging therapeutic targets for solid tumours","authors":"Antonio Saviano, Alberto Toso, Samuel J. Klempner, Thomas F. Baumert","doi":"10.1038/s41568-026-00913-3","DOIUrl":"10.1038/s41568-026-00913-3","url":null,"abstract":"Claudins (CLDNs) are transmembrane proteins that contribute to the epithelial cell polarity and integrity of tight junctions in healthy tissues. CLDNs are frequently overexpressed across different solid tumours, and expression correlates with tumour subtype, grade and prognosis. Dysregulated CLDN expression modulates oncogenic signalling and contributes to tumour proliferation, epithelial–mesenchymal transition, stemness, fibrosis, immune modulation and therapeutic resistance. Owing to their frequent overexpression and functional role in cancer biology, CLDNs have emerged as attractive therapeutic targets. Their surface expression can be exploited to guide therapies into tumours. For example, a monoclonal antibody targeting the CLDN18.2 isoform has reached clinical approval, validating the potential of CLDN-directed approaches. Additional strategies such as antibody–drug conjugates, bispecific and trispecific antibodies and chimeric antigen receptor (CAR) T cells are in development for several CLDN family members. Targeting intracellular CLDN domains or their downstream signalling to disrupt their biological function may offer further promise. Here, we review the functional role of CLDN biology in solid tumours, summarize the clinical development of therapeutic approaches and discuss opportunities for biomarker-enriched patient selection. Collectively, we highlight CLDN targeting as a precision oncology approach relevant to multiple solid tumours. In this Review, Saviano et al. explore the frequent deregulation of claudins (CLDNs) in solid tumours and highlight their role in cancer progression. They discuss strategies to target CLDNs by exploiting tumour-specific surface expression or inhibiting oncogenic signalling and outline knowledge gaps, challenges and opportunities for advancing CLDN-directed cancer therapies.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"26 5","pages":"364-383"},"PeriodicalIF":66.8,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147329234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The intestinal microbiota as a key modulator of acute graft-versus-host disease 肠道菌群作为急性移植物抗宿主病的关键调节因子。

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2026-02-26 DOI: 10.1038/s41568-026-00910-6

Jenny Paredes, Maren Schmiester, Robert Jenq, Marcel R. M. van den Brink

{"title":"The intestinal microbiota as a key modulator of acute graft-versus-host disease","authors":"Jenny Paredes, Maren Schmiester, Robert Jenq, Marcel R. M. van den Brink","doi":"10.1038/s41568-026-00910-6","DOIUrl":"10.1038/s41568-026-00910-6","url":null,"abstract":"Although allogeneic haematopoietic cell transplantation (allo-HCT) is a curative therapy for various malignant diseases, severe complications such as graft-versus-host disease (GVHD) limit its use. The intestinal microbiome has long been known to modulate allo-HCT outcomes. Studies in the past two decades alone have uncovered a complex interplay between the microbial repertoire and the host immune system during allo-HCT. Preclinical studies have characterized the crosstalk between the microbiome and the immune response of the host, discovered associations between microbial taxa and the integrity of the mucosal intestinal barrier, and investigated the role of microbial metabolites in GVHD. Clinical studies have demonstrated that dysbiosis is an independent predictor of both transplantation-related and GVHD-related mortality, and ongoing trials are investigating microbiota-focused approaches to improve clinical outcomes and reduce GVHD severity after allo-HCT, paving the way for therapeutic applications of microbiome research. We anticipate that these insights will support the development of personalized therapies for patients receiving allo-HCT, integrating microbiome profiles with individual risk data. In this Review, we summarize current preclinical and clinical studies, providing a comprehensive account of translational efforts in this highly dynamic field. In this Review, Paredes et al. discuss preclinical and clinical evidence suggesting that the intestinal microbiome influences outcomes of allogeneic haematopoietic cell transplantation and, in particular, graft-versus-host disease and propose that microbiota-focused approaches may improve these clinical outcomes.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"26 5","pages":"328-350"},"PeriodicalIF":66.8,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147308173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0